公开(公告)号：US20110053193A1

公开(公告)日：2011-03-03

申请号：US12298814

申请日：2008-05-22

申请人： Ashley DeAnglis ,  Roberto Meidler ,  Anne Gorman ,  Liliana Bar ,  Israel Nur

发明人： Ashley DeAnglis ,  Roberto Meidler ,  Anne Gorman ,  Liliana Bar ,  Israel Nur

IPC分类号： C12Q1/56

CPC分类号： C12Q1/56 ,  G01N33/68 ,  G01N33/86

摘要： A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

摘要翻译： 描述了在纤维蛋白原存在下测量凝血酶活性或在凝血酶存在下测量纤维蛋白原的功能的方法。

公开(公告)号：US08900822B2

公开(公告)日：2014-12-02

申请号：US13300795

申请日：2011-11-21

申请人： Ashley DeAnglis ,  Elif Burcoglu

发明人： Ashley DeAnglis ,  Elif Burcoglu

IPC分类号： G01N33/53 ,  G01N31/00 ,  G01N33/86

CPC分类号： G01N33/86 ,  G01N27/447

摘要： The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.

摘要翻译： 本发明涉及一种检测完整纤维蛋白原的方法，包括以下步骤：a）提供含有至少一些纤维蛋白原的样品，其至少部分地转化为纤维蛋白，并任选地含有凝血酶; b）将样品溶解在抑制凝血酶活性的增溶溶液中; c）在任选的SDS-PAGE转移/将一部分所述样品施加到蛋白质结合膜之后; d）使纤维蛋白原与能够结合纤维蛋白肽A部分的一级单克隆抗体反应; 和e）通过量化结合的一级单克隆抗体的量来检测样品中完整纤维蛋白原的量。

公开(公告)号：US20130130282A1

公开(公告)日：2013-05-23

申请号：US13300795

申请日：2011-11-21

申请人： Ashley DeAnglis ,  Elif Burcoglu

发明人： Ashley DeAnglis ,  Elif Burcoglu

IPC分类号： G01N33/577 ,  G01N33/559

CPC分类号： G01N33/86 ,  G01N27/447

摘要： The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.